HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Xiaolin Li Selected Research

N-vinyl-2-pyrrolidinone

8/2016Characterization of the Uptake Efficiency and Cytotoxicity of Tetrandrine-Loaded Poly(N-vinylpyrrolidone)-Block-Poly(ε-caprolactone) (PVP-b-PCL) Nanoparticles in the A549 Lung Adenocarcinoma Cell Line.
1/2015Efficient delivery of ursolic acid by poly(N-vinylpyrrolidone)-block-poly (ε-caprolactone) nanoparticles for inhibiting the growth of hepatocellular carcinoma in vitro and in vivo.
1/2014An efficient Trojan delivery of tetrandrine by poly(N-vinylpyrrolidone)-block-poly(ε-caprolactone) (PVP-b-PCL) nanoparticles shows enhanced apoptotic induction of lung cancer cells and inhibition of its migration and invasion.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Xiaolin Li Research Topics

Disease

67Neoplasms (Cancer)
06/2022 - 01/2003
19Infections
12/2022 - 08/2013
12Inflammation (Inflammations)
02/2021 - 05/2007
12Stomach Neoplasms (Stomach Cancer)
03/2020 - 08/2008
11Wounds and Injuries (Trauma)
05/2022 - 05/2009
9Lung Neoplasms (Lung Cancer)
06/2022 - 01/2014
9Neoplasm Metastasis (Metastasis)
04/2022 - 02/2012
8Hypoxia (Hypoxemia)
01/2022 - 09/2014
8Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
12/2021 - 02/2012
7Breast Neoplasms (Breast Cancer)
02/2022 - 01/2016
7Osteosarcoma (Osteogenic Sarcoma)
05/2020 - 02/2016
5Esophagitis
05/2021 - 03/2015
5Hypersensitivity (Allergy)
01/2021 - 01/2006
4Acute Kidney Injury (Acute Renal Failure)
12/2022 - 01/2019
4Neuroinflammatory Diseases
11/2021 - 08/2018
4Hypertension (High Blood Pressure)
09/2021 - 01/2020
4Alzheimer Disease (Alzheimer's Disease)
01/2021 - 01/2014
4Epilepsy (Aura)
01/2019 - 08/2018
4Status Epilepticus (Complex Partial Status Epilepticus)
01/2019 - 06/2016
4Leukemia
10/2017 - 01/2003
4Glioma (Gliomas)
01/2017 - 06/2005
3Sepsis (Septicemia)
12/2022 - 11/2014
3Dermatitis
01/2022 - 01/2016
3Cognitive Dysfunction
11/2021 - 02/2021
3Disease Resistance
04/2021 - 01/2017
3Esophageal Neoplasms (Esophageal Cancer)
01/2021 - 09/2017
3Carcinogenesis
01/2021 - 02/2014
3Atherosclerosis
09/2020 - 04/2010
3Obesity
06/2020 - 05/2019
3Esophageal Squamous Cell Carcinoma
01/2020 - 07/2015
3Insulin Resistance
01/2020 - 12/2015
2Meningoencephalitis
12/2022 - 01/2014
2Type 2 Diabetes Mellitus (MODY)
11/2022 - 01/2020
2Brain Ischemia (Cerebral Ischemia)
11/2021 - 01/2020
2Arthritis (Polyarthritis)
11/2021 - 10/2020
2Stroke (Strokes)
07/2021 - 01/2020
2Pancytopenia
05/2021 - 07/2017
2Bipolar Disorder (Manic Depressive Psychosis)
01/2021 - 01/2017
2Small Cell Lung Carcinoma (Small Cell Lung Cancer)
01/2021 - 01/2017

Drug/Important Bio-Agent (IBA)

15Proteins (Proteins, Gene)FDA Link
11/2021 - 03/2012
14Pharmaceutical PreparationsIBA
01/2022 - 06/2005
9Paclitaxel (Taxol)FDA LinkGeneric
03/2020 - 08/2008
8Biomarkers (Surrogate Marker)IBA
04/2022 - 05/2007
7MicroRNAs (MicroRNA)IBA
12/2022 - 09/2017
7Reactive Oxygen Species (Oxygen Radicals)IBA
06/2022 - 08/2009
7AntioxidantsIBA
05/2022 - 05/2013
6HydrogelsIBA
05/2022 - 01/2016
5epigallocatechin gallate (epigallocatechin-3-gallate)IBA
01/2022 - 01/2016
5ErbB Receptors (EGF Receptor)IBA
12/2021 - 01/2010
5CytokinesIBA
05/2021 - 03/2011
5Peptides (Polypeptides)IBA
07/2020 - 01/2014
5tetrandrineIBA
03/2020 - 08/2010
5ResveratrolIBA
01/2020 - 08/2009
4Messenger RNA (mRNA)IBA
12/2022 - 07/2015
4Glucose (Dextrose)FDA LinkGeneric
11/2022 - 04/2010
4Interleukin-6 (Interleukin 6)IBA
06/2022 - 11/2016
4Hormones (Hormone)IBA
01/2022 - 01/2020
4Transcription Factors (Transcription Factor)IBA
01/2021 - 04/2010
4Pilocarpine (Ocusert)FDA LinkGeneric
01/2019 - 06/2016
3VaccinesIBA
12/2022 - 01/2014
3Therapeutic UsesIBA
04/2022 - 01/2019
3Cyclophosphamide (Cytoxan)FDA LinkGeneric
02/2022 - 01/2020
3SolutionsIBA
01/2022 - 01/2016
3InterferonsIBA
12/2021 - 11/2016
3Small Interfering RNA (siRNA)IBA
01/2021 - 07/2015
3Long Noncoding RNAIBA
01/2021 - 01/2020
3LipidsIBA
09/2020 - 09/2016
3Biological ProductsIBA
05/2020 - 01/2016
3Indicators and Reagents (Reagents)IBA
01/2020 - 03/2009
3Tacrolimus (Prograf)FDA LinkGeneric
01/2019 - 06/2016
3Oxygen (Dioxygen)IBA
01/2019 - 12/2012
3LipopolysaccharidesIBA
09/2018 - 03/2008
3GelatinIBA
01/2018 - 06/2011
3oxidized low density lipoproteinIBA
12/2017 - 09/2016
3Photosensitizing Agents (Photosensitizers)IBA
04/2017 - 06/2005
3methoxy poly(ethylene glycol-co-epsilon-caprolactone)IBA
01/2017 - 01/2016
3N-vinyl-2-pyrrolidinoneIBA
08/2016 - 01/2014
3caprolactoneIBA
08/2016 - 01/2014
3Rituximab (Mabthera)FDA Link
01/2016 - 04/2014
3Antineoplastic Agents (Antineoplastics)IBA
07/2015 - 04/2011
2COVID-19 VaccinesIBA
12/2022 - 04/2022
2CurcuminIBA
06/2022 - 04/2011
2CollagenIBA
05/2022 - 08/2020
2EnzymesIBA
01/2022 - 11/2019
2Tyrosine Kinase InhibitorsIBA
12/2021 - 10/2019
2Biocompatible Materials (Biomaterials)IBA
11/2021 - 05/2018
2asparaginylendopeptidase (legumain)IBA
11/2021 - 10/2021
2Uric Acid (Urate)IBA
11/2021 - 01/2020
2NitratesIBA
10/2021 - 11/2018
2Sericins (Sericin)IBA
07/2021 - 08/2020
2Immune Checkpoint InhibitorsIBA
01/2021 - 07/2020
2AcidsIBA
01/2021 - 01/2021

Therapy/Procedure

39Therapeutics
12/2022 - 06/2005
20Drug Therapy (Chemotherapy)
02/2022 - 04/2011
14Radiotherapy
01/2022 - 02/2012
3Art Therapy
08/2021 - 09/2016
3Intravenous Injections
05/2018 - 11/2014
2Nanospheres
01/2022 - 03/2009
2Adjuvant Radiotherapy
01/2022 - 01/2016
2Injections
07/2021 - 01/2018